[
  {
    "ts": null,
    "headline": "EMD Serono Announces Unprecedented Agreement with U.S. Government to Expand Access to IVF Therapies",
    "summary": "BOSTON, October 16, 2025--EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, and President Donald J. Trump’s administration, today announced an agreement to expand access to the company’s portfolio of in vitro fertilization (IVF) therapies for the more than 10 million American women struggling to have a baby.",
    "url": "https://finnhub.io/api/news?id=fcd3c42618757d02fba5fb8f185db9b3bfab2abf654c8bb929a284d6bc2676ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760644260,
      "headline": "EMD Serono Announces Unprecedented Agreement with U.S. Government to Expand Access to IVF Therapies",
      "id": 137109691,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "BOSTON, October 16, 2025--EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, and President Donald J. Trump’s administration, today announced an agreement to expand access to the company’s portfolio of in vitro fertilization (IVF) therapies for the more than 10 million American women struggling to have a baby.",
      "url": "https://finnhub.io/api/news?id=fcd3c42618757d02fba5fb8f185db9b3bfab2abf654c8bb929a284d6bc2676ae"
    }
  },
  {
    "ts": null,
    "headline": "2 Dow Jones Stocks with Exciting Potential and 1 We Brush Off",
    "summary": "The Dow Jones (^DJI) is home to corporate giants, but size alone doesn’t guarantee success. A few of these companies are struggling with weak fundamentals, paradigm shifts, or poor execution.",
    "url": "https://finnhub.io/api/news?id=f0351241000f4aaf2a5457406c4f455c58a0ae8264743af6ef8e8ced61d40884",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760633080,
      "headline": "2 Dow Jones Stocks with Exciting Potential and 1 We Brush Off",
      "id": 137121709,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Dow Jones (^DJI) is home to corporate giants, but size alone doesn’t guarantee success. A few of these companies are struggling with weak fundamentals, paradigm shifts, or poor execution.",
      "url": "https://finnhub.io/api/news?id=f0351241000f4aaf2a5457406c4f455c58a0ae8264743af6ef8e8ced61d40884"
    }
  },
  {
    "ts": null,
    "headline": "Is Trending Stock Merck & Co., Inc. (MRK) a Buy Now?",
    "summary": "Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=f5d120852c25044de2147c0b2497ce1c4dd0b0e2b35b9be18468785b29e06de8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760619606,
      "headline": "Is Trending Stock Merck & Co., Inc. (MRK) a Buy Now?",
      "id": 137106248,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=f5d120852c25044de2147c0b2497ce1c4dd0b0e2b35b9be18468785b29e06de8"
    }
  },
  {
    "ts": null,
    "headline": "Merck Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients With Platinum-Resistant Recurrent Ovarian Cancer",
    "summary": "RAHWAY, N.J., October 16, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, met its secondary endpoint of overall survival (OS) for the treatment of patients with platinum-resistant recurrent ovarian cancer in all comers. The trial studied KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab for these patients. As pr",
    "url": "https://finnhub.io/api/news?id=4cfff1d4c7bf89cd392c5ffc54e5fa9fbb7c21da923efef94eb28638a7efa074",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760611500,
      "headline": "Merck Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients With Platinum-Resistant Recurrent Ovarian Cancer",
      "id": 137104540,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., October 16, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, met its secondary endpoint of overall survival (OS) for the treatment of patients with platinum-resistant recurrent ovarian cancer in all comers. The trial studied KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab for these patients. As pr",
      "url": "https://finnhub.io/api/news?id=4cfff1d4c7bf89cd392c5ffc54e5fa9fbb7c21da923efef94eb28638a7efa074"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Earnings Outlook Steady, Keytruda Now Has Some Breathing Room",
    "summary": "Merck leads U.S. pharma in 2025, but faces Keytruda patent loss by 2028. Click for my look at MRK stock ahead of its upcoming Q3 earnings release.",
    "url": "https://finnhub.io/api/news?id=4da35621f2b556530db24678043e06ff991a116fc5bec80afc74bbffca16cbf4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760601600,
      "headline": "Merck: Earnings Outlook Steady, Keytruda Now Has Some Breathing Room",
      "id": 137103945,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2190092347/image_2190092347.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck leads U.S. pharma in 2025, but faces Keytruda patent loss by 2028. Click for my look at MRK stock ahead of its upcoming Q3 earnings release.",
      "url": "https://finnhub.io/api/news?id=4da35621f2b556530db24678043e06ff991a116fc5bec80afc74bbffca16cbf4"
    }
  },
  {
    "ts": null,
    "headline": "Citi Raises Price Target on Merck (MRK), Citing Strong Pipeline and Oncology Strength",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 11 Defensive Healthcare Dividend Stocks to Buy Now. Merck & Co., Inc. (NYSE:MRK) is a global pharmaceutical company recogni⁠zed for its strong onco⁠l‌ogy lineup, led by‍ its fl⁠agsh⁠ip drug⁠ Keytruda, the top-selling medicin‌e in the w‌orld. The company also prod⁠u‍ces tre‌atments⁠ for diabetes, as well as […]",
    "url": "https://finnhub.io/api/news?id=084d4dcdbe15a4e6442e2b757d3e48b15cb8bbe0a0e855b253a83e8fe1de0743",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760594786,
      "headline": "Citi Raises Price Target on Merck (MRK), Citing Strong Pipeline and Oncology Strength",
      "id": 137102015,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 11 Defensive Healthcare Dividend Stocks to Buy Now. Merck & Co., Inc. (NYSE:MRK) is a global pharmaceutical company recogni⁠zed for its strong onco⁠l‌ogy lineup, led by‍ its fl⁠agsh⁠ip drug⁠ Keytruda, the top-selling medicin‌e in the w‌orld. The company also prod⁠u‍ces tre‌atments⁠ for diabetes, as well as […]",
      "url": "https://finnhub.io/api/news?id=084d4dcdbe15a4e6442e2b757d3e48b15cb8bbe0a0e855b253a83e8fe1de0743"
    }
  },
  {
    "ts": null,
    "headline": "From Magnificent To Stretched: Rethink U.S. Equity Allocations",
    "summary": "A small number of companies dominate US equity market size and earnings, making investors reliant on the fortunes of a select few.",
    "url": "https://finnhub.io/api/news?id=bcb384d44917522deadb7813a6f0f1fd74ab1db745201614fd17e6bcd5b5a001",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760594640,
      "headline": "From Magnificent To Stretched: Rethink U.S. Equity Allocations",
      "id": 137103600,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2007398242/image_2007398242.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "A small number of companies dominate US equity market size and earnings, making investors reliant on the fortunes of a select few.",
      "url": "https://finnhub.io/api/news?id=bcb384d44917522deadb7813a6f0f1fd74ab1db745201614fd17e6bcd5b5a001"
    }
  },
  {
    "ts": null,
    "headline": "Germany’s Merck Sets Out Midterm Sales Growth, Profitability Expansion Targets",
    "summary": "The company confirmed its 2025 guidance and is targeting annual organic sales growth in the mid-single-digit percentage range and an expansion in profitability over the medium term.",
    "url": "https://finnhub.io/api/news?id=c59a1083e71fa1f9f5a62d5b5d17f5500a715fe7a8d83e16ce9a14a239454253",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760594400,
      "headline": "Germany’s Merck Sets Out Midterm Sales Growth, Profitability Expansion Targets",
      "id": 137102016,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The company confirmed its 2025 guidance and is targeting annual organic sales growth in the mid-single-digit percentage range and an expansion in profitability over the medium term.",
      "url": "https://finnhub.io/api/news?id=c59a1083e71fa1f9f5a62d5b5d17f5500a715fe7a8d83e16ce9a14a239454253"
    }
  },
  {
    "ts": null,
    "headline": "1 Profitable Stock Worth Your Attention and 2 Facing Challenges",
    "summary": "Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.",
    "url": "https://finnhub.io/api/news?id=6d673d7f55bec42f77c48ee0dd8d0d90a7376f2426b50da3b3f9a183fcb462f3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760589551,
      "headline": "1 Profitable Stock Worth Your Attention and 2 Facing Challenges",
      "id": 137104541,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.",
      "url": "https://finnhub.io/api/news?id=6d673d7f55bec42f77c48ee0dd8d0d90a7376f2426b50da3b3f9a183fcb462f3"
    }
  }
]